Britain and America have concluded a major trade agreement that will preserve zero import taxes on British drug products going into the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to raise funding on drugs through the public health system. This move guarantees that duties on these key exports will remain at zero for a duration of 36 months.
This agreement is in response to recent warnings to dramatically increase duties on patented drug products, with figures mentioned reaching one hundred percent.
"This agreement between the United Kingdom strengthens the global environment for cutting-edge drugs and introduces much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Medicines constitute one of the UK's largest export categories to the United States, which is by far the primary destination for leading companies like GSK and AstraZeneca.
Statistics show that in the year prior to last September, the UK shipped drugs worth over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that span.
"This deal protects employment, stimulates capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal involves several specific changes from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double total public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to control costs will be limited at fifteen percent. Previously, refunds topped twenty percent.
Industry Background
The pact takes place against a protracted tension between the drug companies and the British authorities over spending levels and approval rates.
This friction were heightened by claims that US consumers were paying several times more for the equivalent treatments than consumers in the other developed nations.
In recent months, several major manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the past decade.
